A new review in Cureus pulls together efficacy and safety evidence on orforglipron, the daily pill alternative to injectable GLP-1 drugs.
Recap by typeshit. Full story at Cureus.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
The 80-week Lancet trial of 1,152 adults saw 47% on the 12 mg dose lose at least 20% of their weight, with more nausea and diarrhea than placebo.
Lilly says it has reported over 14,000 listings and referred 200+ sellers to regulators. One analyst puts the illicit price near $200 a month.
Loading…